Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumor 1Recurrence 1Nasopharyngeal Carcinoma 1Carcinoma, Renal Cell 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × famitinib × Clear all
NCT02390947 2020-12-22

FACT

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
543 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01762293 2018-04-18

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
154 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡